HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 27, 2010, Pages 12381-12386

  Supervie, Virginie ^a,c   García Lerma, J Gerardo ^b   Heneine, Walid ^b   Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSERM   (France)

Author keywords

Antiretrovirals; Epidemics; Mathematical model; Men who have sex with men; Prevention

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; VIRUS LOAD;

ALGORITHMS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALE; MODELS, THEORETICAL; MONTE CARLO METHOD; SAN FRANCISCO; VIRULENCE;

EID: 77955454024     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1006061107     Document Type: Article

References (44)

1. Paxton LA, Hope T, Jaffe HW (2007) Pre-exposure prophylaxis for HIV infection: What if it works? Lancet 370:89-93.
2. AVAC (2010) PrEP clinical trials. Available at http://www.avac.org/ht/d/ sp/i/3507/pid/ 3507. Accessed April 30, 2010.
3. Peterson L, et al. (2007) Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2:e27. (Pubitemid 351728642)
4. Abdool Karim SS, Baxter C (2009) Antiretroviral prophylaxis for the prevention of HIV infection: Future implementation challenges. HIV Ther 3:3-6.
5. Booth CL, Geretti AM (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056.
6. Eshleman SH, et al. (2007) Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 21: 1165-1174.
7. Little SJ, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347:385-394. (Pubitemid 34851830)
8. Little SJ, et al. (2006) Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir Ther 11:S110.
9. Ross LL, et al. (2006) Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral therapy (ART) naive HIV-infected individuals in the United States from 2000-2004. Antivir Ther 11:S120.
10. Bryant J, Baxter L, Hird S (2009) Non-occupational postexposure prophylaxis for HIV: A systematic review. Health Technol Assess 13:1-82.
11. Grant RM, Wainberg MA (2006) Chemoprophylaxis of HIV infection: Moving forward with caution. J Infect Dis 194:874-876.
12. Liu AY, Grant RM, Buchbinder SP (2006) Preexposure prophylaxis for HIV: Unproven promise and potential pitfalls. JAMA 296:863-865.
13. Leigh Brown AJ, et al. (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187:683-686.
14. Murray JM (2003) Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy. J Infect Dis, 188:1258 author reply 1258-1259..
15. Van de Vijver DAMC, et al. (2005) Selective transmission of drug resistance mutations. Antivir Ther 10:S126.
16. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S (2010) Evolutionary dynamics of complex networks of HIV drug-resistant strains: The case of San Francisco. Science 327:697-701.
17. García-Lerma JG, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5:e28.
18. Subbarao S, et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194:904-911. (Pubitemid 44454075)
19. Van Rompay KK, et al. (2000) Prophylactic and therapeutic benefits of short-term 9- [2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 74:1767-1774.
20. Veazey RS, et al. (2005) Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11:1293-1294. (Pubitemid 41752908)
21. Prada N, et al. (2008) Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr 49:117-122.
22. García-Lerma JG, et al. (2010) Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med 2:14ra4.
23. Quinn TC, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342:921-929.
24. Dyer JR, et al. (1998) High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 177:1742-1746.
25. Operskalski EA, et al. (1997) Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol 146:655-661.
26. Smith RJ, Blower SM (2004) Could disease-modifying HIV vaccines cause populationlevel perversity? Lancet Infect Dis 4:636-639.
27. Wawer MJ, et al. (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191:1403-1409.
28. Smith D, et al. (2007) Clinical utility of HIV standard genotyping among antiretroviralnaive individuals with unknown duration of infection. Clin Infect Dis 44:456-458. (Pubitemid 46147633)
29. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J (1999) Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-2546. (Pubitemid 30038032)
30. Devereux HL, Youle M, Johnson MA, Loveday C (1999) Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13:F123-F127. (Pubitemid 30038026)
31. Brodard V, et al. (2005) Prevalence of detection and dynamics of selection and reversion of K65R mutation in nucleoside reverse transcriptase inhibitor-experienced patients failing an antiretroviral regimen. J Acquir Immune Defic Syndr 39:250-253. (Pubitemid 40741126)
32. Fiebig EW, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
33. Owen SM, et al. (2008) Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 46:1588-1595.
34. Rose KA, Smith EP, Gardner RH, Brenkert AL, Bartell SM (2006) Parameter sensitivities, Monte Carlo filtering, and model forecasting under uncertainty. J Forecast 10: 117-133.
35. Osmond DH, Pollack LM, Paul JP, Catania JA (2007) Changes in prevalence of HIV infection and sexual risk behavior in men who have sex with men in San Francisco: 1997-2002. Am J Public Health 97:1677-1683. (Pubitemid 351182334)
36. Brenner BG, et al. (2002) Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76:1753-1761. (Pubitemid 34094622)
37. Cane PA (2005) Stability of transmitted drug-resistant HIV-1 species. Curr Opin Infect Dis 18:537-542.
38. Pao D, et al. (2004) Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 37:1570-1573.
39. Xiridou M, Geskus R, de Wit J, Coutinho R, Kretzschmar M (2004) Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS 18:1311-1320. (Pubitemid 38822710)
40. Pinkerton SD (2007) How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS 21:1625-1629.
41. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH (2009) Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 50:77-83.
42. Liu AY, et al. (2008) Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 47:241-247.
43. Blower SM, Gershengorn HB, Grant RM (2000) A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 287:650-654.
44. Blower SM, Dowlatabadi H (1994) Sensitivity and uncertainty analysis of complex models of disease transmission-An HIV model, as an example. Int Stat Rev 62: 229-243.